- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05641298
Study to Determine the Efficacy&Safety of ARV-1801(ACG-701) for the Treatment of Cystic Fibrosis Pulmonary Exacerbations (REPRIEVE)
A Phase 2, Randomized, DB, Placebo-controlled Study to Determine the Efficacy, Safety and PK Profile of ARV-1801 in Combination With Optimized Background Therapy for the Treatment of Pulmonary Exacerbations in Patients With Cystic Fibrosis
Study Overview
Status
Intervention / Treatment
Detailed Description
This is a Phase 2, randomized, double-blind, multicenter study designed to evaluate the efficacy and safety of an oral ARV-1801/ACG-701 plus OBT compared to oral placebo plus OBT, each administered for 14 days, in the treatment of participants with CF-related PEx.
Participants who provide informed consent (plus informed assent, if applicable) and meet all study eligibility criteria will be enrolled in the study and randomized via an interactive response technology (IRT) in a 1:1 ratio to receive ARV-1801/ACG-701 or placebo in addition to OBT for 14 days. A participant may be hospitalized (inpatient) or treated as an outpatient. If admitted to the hospital for initial treatment, the participant may be discharged at the Investigator's discretion to complete study therapy as an outpatient. The target study population will comprise 80 participants.
The duration of participation in the study for an individual participant will be approximately 28 days and will involve up to 5 clinic visits as well as the requirement to complete an electronic symptom questionnaire every day for the duration of the study. Participation will include a Screening period of up to 24 hours prior to the first dose of study drug (Day 1), a 14 day treatment course of study drug, a Day 7 visit (±1 day), an end of treatment (EOT) visit (day of last dose of study drug +3 days), and end of study (EOS) visit on Day 28 (+3 days).
Study Type
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Christina Lockhart, MBA
- Phone Number: 919-366-5500
- Email: patientinfo@aceragen.com
Study Locations
-
-
Florida
-
Gainesville, Florida, United States, 32610
- University of Florida
-
Orlando, Florida, United States, 32803
- Central Florida Pulmonary Group
-
Pensacola, Florida, United States, 32514
- Nemours Children's Health - Pensacola
-
Saint Petersburg, Florida, United States, 33701
- Johns Hopkins All Children's Hospital
-
-
Illinois
-
Chicago, Illinois, United States, 60093
- Cystic Fibrosis Center of Chicago
-
Northfield, Illinois, United States, 60093
- Cystic Fibrosis Center of Chicago
-
-
Indiana
-
Indianapolis, Indiana, United States, 46202
- Riley Hospital for Children
-
-
Kansas
-
Kansas City, Kansas, United States, 66160
- University of Kansas Medical Center
-
-
Kentucky
-
Louisville, Kentucky, United States, 40202
- University of Louisville
-
-
Maine
-
Portland, Maine, United States, 04102
- Maine Medical Center
-
-
Maryland
-
Baltimore, Maryland, United States, 21287
- Johns Hopkins University
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
- University of Michigan, Michigan Medicine
-
-
Missouri
-
Saint Louis, Missouri, United States, 63114
- Washington University School of Medicine
-
-
Nebraska
-
Omaha, Nebraska, United States, 68114
- UNMC-Nebraska CF Pediatric Center
-
-
New Jersey
-
Morristown, New Jersey, United States, 07960
- Gunnar H. Esiason Adult Cystic Fibrosis Center
-
-
New York
-
Hawthorne, New York, United States, 10532
- New York Medical College
-
Rochester, New York, United States, 14642
- University of Rochester Medical Center Strong Memorial
-
-
Ohio
-
Cleveland, Ohio, United States, 44106
- Rainbow Babies and Children's Hospital/Cleveland Medical Center
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States, 73104
- University of Oklahoma Health Sciences Center
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15224
- University of Pittsburgh Medical Center
-
-
South Carolina
-
Charleston, South Carolina, United States, 29425
- Medical University of South Carolina
-
-
Tennessee
-
Nashville, Tennessee, United States, 37232
- Vanderbilt University Medical Center
-
-
Texas
-
Fort Worth, Texas, United States, 76104
- Cook Children's Health Care System
-
Tyler, Texas, United States, 75708
- The University of Health Science Center at Tyler
-
-
Washington
-
Spokane, Washington, United States, 99204
- Providence Medical Research Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Males and females of 12 years of age and older
Participants must have a confirmed diagnosis of Cystic Fibrosis with a diagnosis of an acute pulmonary exacerbation as defined as:
- Deterioration in 3 or more of the following symptoms for at least 48 hrs (cough, sputum volume and/or consistency, sputum purulence, breathlessness and/or exercise tolerance, fatigue and/or malaise, or hemoptysis) And
- a clinician determines that a change in CF treatment is required
- Participants must have a CFRSD-CRISS score of >/= 35
- Participants must have a moderate or Severe Patient Global Impression of Severity
- Participants must have a negative pregnancy test and agree to use a highly effective method of contraception during the study and 30 days after last dose
- Participants must agree not to smoke during any part of the clinical trial
- Participants must voluntarily sign the informed consent for the study
Exclusion Criteria:
- Participants cannot have any changes in any antimicrobial, bronchodilator, anti-inflammatory, CFTR modulator or corticosteroid medications from 28 - 3 days prior to the Screening visit.
- Participants cannot be receiving treatment for non-tuberculosis mycobacteria and/or Aspergillus infection.
- History of hypersensitivity or allergic reaction to sodium fusidate, fusidic acid (Fucidin®) or its excipients.
- Abnormal laboratory findings or other findings or medical history at Screening that, in the Investigator's opinion, would compromise the safety of the participant or the quality of the study data.
- The use of an investigational drug or device (ie, a drug or device without the FDA approved indication) within 30 days prior to the Screening visit
- Known severe renal impairment, as indicated by estimated creatinine clearance (CrCl) <30 mL/min (by Cockcroft-Gault calculation).
- Evidence of significant liver disease: ALT >3×ULN, or direct bilirubin >ULN, or total bilirubin >1.5 mg/dL; known cirrhosis with decompensation (ie, Child-Pugh Class B or C disease).
- Known hepatitis C virus (HCV) or infection and currently receiving HCV-specific antiviral therapy. HCV infection alone, and in the absence of decompensated liver disease, is not exclusionary.
- Neutropenia (absolute neutrophil count <500/µL); thrombocytopenia (<60,000 platelets/mm3).
- Known human immunodeficiency virus (HIV) infection and currently receiving antiretroviral therapy, or current CD4 count ≤200 cells/mm3 (documented within 3 months prior to enrollment); if CD4 count is unknown, participant may not enroll.
- Changes to or initiation of immunosuppressant agents (ie, prednisone [≥15mg/day], cyclosporine, tumor necrosis factor alpha [TNFα] antagonist) within 30 days of study medication administration through the EOS visit.
- Malignancy requiring ongoing cytotoxic chemotherapy or radiation therapy.
Requires concomitant treatment with (washout period prior to randomization allowed):
- OATP1B1 and OATP1B3 substrates (eg, HMG-CoA reductase inhibitors [statins])
- CYP2C8 substrates, namely glitazones (eg, repaglinide)
- CYP3A4 inducers (eg, dexamethasone, phenytoin, carbamazepine, rifampin, phenobarbital, nafcillin)
- Moderate/strong CYP3A4 inhibitors (eg, azole antifungals, erythromycin, clarithromycin)
- P-gp substrates with narrow therapeutic windows (eg, digoxin and colchicine)
- Prior treatment with a CYP3A4 inducer (such as lumacaftor, dexamethasone, phenytoin, carbamazepine, rifampin, phenobarbital and nafcillin) within 7 days prior to enrollment.
- Dietary use of large amounts of grapefruit juice and/or Seville oranges or other products containing these fruits (eg, grapefruit juice or marmalade) during the study.
- Participant requiring warfarin therapy.
- Seizure disorder requiring current therapy with an anticonvulsant.
- Female participant who is pregnant or lactating.
- History of /current chronic alcohol consumption and/or drug abuse (including cannabis use).
- Any study personnel or their immediate dependents, family, or household members.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo Group
Placebo tablets by mouth twice a day for 14 days
|
Tablets
|
Active Comparator: ARV-1801(ACG-701) Active Group
ARV-1801(ACG-701) tablets by mouth twice a day for 14 days
|
Tablets
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Desirability in outcome ranking (DOOR)
Time Frame: Day 7
|
To demonstrate that the addition of oral ARV-1801(ACG-701) to OBT is superior to placebo plus OBT based on DOOR in cystic fibrosis pulmonary exacerbations.
|
Day 7
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Pathologic Processes
- Respiratory Tract Diseases
- Lung Diseases
- Infant, Newborn, Diseases
- Genetic Diseases, Inborn
- Pancreatic Diseases
- Lung Diseases, Interstitial
- Fibrosis
- Pulmonary Fibrosis
- Cystic Fibrosis
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Enzyme Inhibitors
- Anti-Bacterial Agents
- Protein Synthesis Inhibitors
- Fusidic Acid
Other Study ID Numbers
- ACG-701-101
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cystic Fibrosis
-
Hospital de Clinicas de Porto AlegreUnknownCystic Fibrosis | Cystic Fibrosis Pulmonary Exacerbation | Cystic Fibrosis in Children | Cystic Fibrosis With ExacerbationBrazil
-
University of Colorado, DenverCystic Fibrosis FoundationTerminatedCystic Fibrosis-related Diabetes | Cystic Fibrosis Pulmonary Exacerbation | Cystic Fibrosis in ChildrenUnited States
-
Royal College of Surgeons, IrelandThe Hospital for Sick Children; Imperial College London; Erasmus Medical Center; University College Dublin and other collaboratorsActive, not recruitingCystic Fibrosis | Adherence, Medication | Cystic Fibrosis Gastrointestinal Disease | Cystic Fibrosis in Children | Cystic Fibrosis Liver DiseaseUnited Kingdom, Ireland
-
Herlev and Gentofte HospitalCopenhagen University Hospital, DenmarkActive, not recruitingMyocardial Infarction | Heart Diseases | Heart Failure | Stroke | Cystic Fibrosis | Heart Failure, Diastolic | Heart Failure, Systolic | Left Ventricular Dysfunction | Cystic Fibrosis-related Diabetes | Cystic Fibrosis Gastrointestinal Disease | Cystic Fibrosis of Pancreas | Cystic Fibrosis, Pulmonary | Cystic...Denmark
-
The Hospital for Sick ChildrenCanadian Cystic Fibrosis FoundationActive, not recruitingCystic Fibrosis | Cystic Fibrosis Gastrointestinal Disease | Cystic Fibrosis in ChildrenCanada
-
Arrowhead PharmaceuticalsTerminatedCystic Fibrosis, PulmonaryAustralia, New Zealand
-
AzurRx SASCompletedCystic Fibrosis | Cystic Fibrosis Gastrointestinal Disease | Cystic Fibrosis of PancreasTurkey, Hungary
-
Dartmouth-Hitchcock Medical CenterTrustees of Dartmouth CollegeWithdrawnCystic Fibrosis-related Diabetes | Cystic Fibrosis Liver Disease | CF - Cystic FibrosisUnited States
-
University Hospital, BordeauxCompleted
-
Mack Biotech, Corp.Completed
Clinical Trials on Sodium Fusidate
-
Arrevus Inc.CompletedRefractory Bone or Joint InfectionsUnited States
-
Arrevus Inc.CompletedAcute Bacterial Skin and Skin Structure InfectionsUnited States, Puerto Rico
-
Indonesia UniversityCompletedSeborrheic Keratosis | AcrochordonIndonesia
-
University of DelawareCompletedBlood Pressure | Cerebrovascular ReactivityUnited States
-
Institut d'Anesthesiologie des Alpes MaritimesUniversité de Nice Sophia Antipolis; Medical University of GrenobleCompleted
-
Radboud University Medical CenterUnknownType1diabetes | Hypoglycemia UnawarenessNetherlands
-
Austin HealthCompletedSystemic Inflammatory Response Syndrome | Renal Impairment | OliguriaAustralia
-
Medical University of GrazCompleted
-
Brigham and Women's HospitalCompleted